MicroPort NeuroTech

MicroPort NeuroTech operates in the specialized neurovascular medical-device segment, addressing hemorrhagic stroke, intracranial atherosclerotic disease, and acute ischemic stroke. Its competitive position is defined less by a single flagship product than by portfolio breadth: Tubridge™ targets intracranial aneurysms, NeuroHawk® supports mechanical thrombectomy, WAVE-track™ addresses aspiration thrombectomy, and the company also offers balloon catheters, guiding catheters, guidewires, and stent systems. This breadth allows it to participate across multiple stages of neurointerventional procedures and may support hospital-level adoption. The company reports use in more than 3,300 Chinese hospitals and product availability in over 30 countries, providing a meaningful commercial footprint for a Shanghai-based manufacturer. Its $150 million 2021 financing and ownership by MicroPort Shanghai indicate access to substantial healthcare-industry backing, while its differentiation appears to rest on localized clinical collaboration, a broad stroke-care portfolio, and international expansion.

MicroPort NeuroTech’s trajectory shows a transition from a Shanghai-founded development company into a scaled neurovascular-device platform. Founded in May 2012, it raised $150 million in a venture round announced on Nov 12, 2021, with CICC Healthcare Investment Fund and Huayi Capital participating. The 2022 Hong Kong debut marked a further corporate-finance inflection point, although current ownership and operating-status fields identify the business as active and associated with MicroPort Shanghai. Product expansion is the clearest operational growth signal. The portfolio now covers flow diversion, intracranial stenting, thrombectomy, aspiration, carotid dilation, balloon guidance, and device navigation, reducing dependence on a single procedure category. By November 2024, the company reported products in more than 3,300 hospitals across China, support for over 420,000 patients, and availability in more than 30 countries. The 2024 Tubridge™ publication and the company’s expectation of a 2023 profit swing suggest increasing commercialization maturity. The company’s next growth phase therefore remains difficult to quantify.